Compare ANIP & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | PSNY |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | ANIP | PSNY |
|---|---|---|
| Price | $77.36 | $18.44 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $107.33 | $15.00 |
| AVG Volume (30 Days) | ★ 419.1K | 289.3K |
| Earning Date | 02-27-2026 | 03-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | $826,880,000.00 | ★ $2,547,619,000.00 |
| Revenue This Year | $44.19 | $49.69 |
| Revenue Next Year | $11.25 | $44.50 |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | ★ 48.87 | 24.82 |
| 52 Week Low | $54.10 | $11.75 |
| 52 Week High | $99.50 | $42.60 |
| Indicator | ANIP | PSNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 55.94 |
| Support Level | $75.30 | $17.65 |
| Resistance Level | $83.80 | $19.33 |
| Average True Range (ATR) | 2.51 | 1.77 |
| MACD | -0.54 | 0.09 |
| Stochastic Oscillator | 20.59 | 76.37 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.